

Table 1. Longitudinal changes in patient characteristics, risperidone levels, and glycemic and hormonal parameters; *N* = 10.

Parameter	Baseline	6-month follow-up	Baseline vs 6-month follow-up
	Median (IQR)		p-value
Patient characteristics			
Age, years	9.70 (7.57-12.03)	NA	NA
Weight, kg	32.80 (26.13-53.48)	37.22 (29.95-60.55)	< 0.001 *a
BMI z-score	0.35 (-0.28-0.98)	0.97 (0.12-1.62)	< 0.001 *a
Male, n (%)	8 (80%)	NA	NA
Risperidone			
Dosage, mg/day	NA	0.63 (0.5-1)	NA
Sum_trough level µg/L	NA	9.6 (6.8-12.8)	NA
Cumulative AUC mg/L.h	NA	44.05 (34.86-62.25)	NA
Glycemic parameters			
Glucose, mg/L	4.9 (4.7-5.1)	4.9 (4.6-5.4)	0.488 ^a
Insulin, U/L	47 (23-60)	59 (27-88)	0.220 ^a
HOMA-IR	1.7 (0.9-2.2)	2.3 (0.9-3.0)	0.226 ^a
Hormonal levels			
Leptin, ug/L	2.3 (0.9-4.4)	3.8 (2.8-8.4)	0.154 ^b
Bioleptin, ug/L	2.9 (1.3-5.8)	5.1 (3.3-7.3)	0.042 ^{*b}
Bioleptin/leptin ratio	1.29 (1.11-1.42)	1.21 (1.10-1.37)	0.945 ^b

Abbreviations: BMI z-score, body mass index adjusted for age and gender; HOMA, homeostasis model assessment of insulin resistance; AUC, Area Under the Curve.

*: significance level $p < 0.05$

a: Paired t-test

b: Wilcoxon rank test

